Dr MBA - Tonix Pharmaceuticals Executive Research
| TNXP Stock | USD 0.19 0.01 5.00% |
Executive
Dr MBA is Executive Research of Tonix Pharmaceuticals Holding
| Age | 66 |
| Address | 26 Main Street, Chatham, NJ, United States, 07928 |
| Phone | 862 799 8599 |
| Web | https://www.tonixpharma.com |
Tonix Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.5172) % which means that it has lost $0.5172 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.6324) %, meaning that it created substantial loss on money invested by shareholders. Tonix Pharmaceuticals' management efficiency ratios could be used to measure how well Tonix Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of 11/24/2024, Return On Tangible Assets is likely to drop to -0.85. In addition to that, Return On Capital Employed is likely to drop to -0.92. At this time, Tonix Pharmaceuticals' Total Current Liabilities is relatively stable compared to the past year. As of 11/24/2024, Liabilities And Stockholders Equity is likely to grow to about 162.2 M, while Non Current Liabilities Other is likely to drop slightly above 436 K.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Silvia MBA | Novavax | N/A | |
| E MBA | Inovio Pharmaceuticals | N/A | |
| Felipe Duran | Ibio Inc | 45 | |
| Sean Tucker | Vaxart Inc | 56 | |
| Rajesh Kapoor | Vaxart Inc | N/A | |
| MBA MA | Inovio Pharmaceuticals | N/A | |
| Nigel MSc | Virax Biolabs Group | 59 | |
| Laurent Humeau | Inovio Pharmaceuticals | 57 | |
| Clement Monteil | Virax Biolabs Group | N/A | |
| Elaine OHara | Novavax | 56 | |
| Kevin CPA | Enveric Biosciences | 60 | |
| Peter Hodge | Jaguar Animal Health | N/A | |
| Robert JD | Inovio Pharmaceuticals | 50 | |
| Peter Kies | Inovio Pharmaceuticals | 61 | |
| Joerg Heyer | Palisade Bio | N/A | |
| Erika Trahan | Novavax | N/A | |
| JD Esq | Novavax | 53 | |
| Robert Juba | Inovio Pharmaceuticals | N/A | |
| Gael Hedou | Sonnet Biotherapeutics Holdings | 52 | |
| Marc JD | Ibio Inc | N/A | |
| James Wang | Virax Biolabs Group | N/A | |
Management Performance
| Return On Equity | -1.63 | ||||
| Return On Asset | -0.52 |
Tonix Pharmaceuticals Leadership Team
Elected by the shareholders, the Tonix Pharmaceuticals' board of directors comprises two types of representatives: Tonix Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Tonix. The board's role is to monitor Tonix Pharmaceuticals' management team and ensure that shareholders' interests are well served. Tonix Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Tonix Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Seth MD, President, CoFounder | ||
| CPA CPA, CFO Treasurer | ||
| Bradley CPA, CFO Treasurer | ||
| Daniel MD, Consultant | ||
| Dr MBA, Executive Research | ||
| Gregory MD, Chief Secretary | ||
| M Morris, Acting CFO and Chief Admin. Officer | ||
| Sina Bavari, Executive Development | ||
| Thomas Englese, Executive Operations | ||
| Darryl Rideout, Executive Chemistry | ||
| MPH MD, Executive Medical | ||
| James MBA, Executive Operations |
Tonix Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Tonix Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.63 | ||||
| Return On Asset | -0.52 | ||||
| Operating Margin | (8.31) % | ||||
| Current Valuation | 15.97 M | ||||
| Shares Outstanding | 186.89 M | ||||
| Shares Owned By Insiders | 0.16 % | ||||
| Shares Owned By Institutions | 0.23 % | ||||
| Number Of Shares Shorted | 7.67 M | ||||
| Price To Earning | (0.69) X | ||||
| Price To Book | 0.48 X |
Pair Trading with Tonix Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Tonix Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Tonix Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with Tonix Stock
Moving against Tonix Stock
The ability to find closely correlated positions to Tonix Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Tonix Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Tonix Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Tonix Pharmaceuticals Holding to buy it.
The correlation of Tonix Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Tonix Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Tonix Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Tonix Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Tonix Stock Analysis
When running Tonix Pharmaceuticals' price analysis, check to measure Tonix Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tonix Pharmaceuticals is operating at the current time. Most of Tonix Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Tonix Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tonix Pharmaceuticals' price. Additionally, you may evaluate how the addition of Tonix Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.